Gingold Julian A, Wu Haotian, Lieman Harry, Singh Manvinder, Jindal Sangita
Montefiore Institute for Reproductive Medicine and Health, OB/GYN & Women's Health, Hartsdale, New York.
Mailman School of Public Health, Columbia University, New York, New York.
F S Rep. 2023 Oct 29;5(1):23-32. doi: 10.1016/j.xfre.2023.10.004. eCollection 2024 Mar.
To compare clinical outcomes between nonindicated intracytoplasmic sperm injection (ICSI) and conventional insemination.
Autologous cycles performed from 2014-2017 were identified, excluding frozen oocyte cycles. Outcomes were compared between conventional insemination (in vitro fertilization [IVF]) and nonindiated ICSI and analyzed separately for fresh, frozen-thawed preimplantation genetic testing (PGT) and frozen-thawed non-PGT cycles.
US-based fertility clinics reporting to the Society for Assisted Reproductive Technology.
A total of 187,520 patients underwent 318,930 cycles, 57,516 (18.0%) using conventional IVF and 261,414 ICSI (82.0%).
Intracytoplasmic sperm injection, with or without indications (male factor, prior fertilization failure or any PGT [2012 recommendations]/single-gene PGT [2020 recommendations]).
Odds ratios (ORs) for live birth rates and clinical pregnancy rates were calculated after multivariable adjustment for maternal age, body mass index, infertility etiologies, prior IVF births, and number oocytes retrieved.
Intracytoplasmic sperm injection was indicated in 151,627 (58.0%) of cycles according to 2012 American Society for Reproductive Medicine Practice Committee recommendations, and 108,895 (41.7%) according to 2020 recommendations. In multivariable models, nonindicated ICSI among fresh cycles was associated with reduced odds of completing a blastocyst-stage transfer (OR, 0.72; 95% confidence interval [CI] [0.7, 0.75]; <.001), resulting in reduced odds of live birth (OR, 0.80; 95% CI [0.78, 0.83]; <.001). Among completed fresh transfers, clinical pregnancy and live birth rates were comparable between nonindicated ICSI and IVF. Nonindicated ICSI in frozen-thawed cycles with PGT and without PGT was associated with comparable live birth and clinical pregnancy rates with IVF in multivariable models.
Nonindicated ICSI was associated with reduced blastocyst availability in fresh cycles compared with IVF, leading to lower live birth rates. Outcomes from completed transfers were clinically comparable.
比较非适应证卵胞浆内单精子注射(ICSI)与传统授精的临床结局。
确定2014年至2017年进行的自体周期,不包括冷冻卵母细胞周期。比较传统授精(体外受精[IVF])和非适应证ICSI的结局,并分别对新鲜、冻融胚胎植入前遗传学检测(PGT)和冻融非PGT周期进行分析。
向辅助生殖技术协会报告的美国生育诊所。
共有187,520例患者进行了318,930个周期,其中57,516个(18.0%)采用传统IVF,261,414个采用ICSI(82.0%)。
卵胞浆内单精子注射,有或无适应证(男性因素、既往受精失败或任何PGT[2012年建议]/单基因PGT[2020年建议])。
在对产妇年龄、体重指数、不孕病因、既往IVF分娩情况和获取的卵母细胞数量进行多变量调整后,计算活产率和临床妊娠率的比值比(OR)。
根据2012年美国生殖医学学会实践委员会的建议,151,627个(58.0%)周期有ICSI适应证,根据2020年建议为108,895个(41.7%)。在多变量模型中,新鲜周期中的非适应证ICSI与完成囊胚期移植的几率降低相关(OR,0.72;95%置信区间[CI][0.7, 0.75];P<.001),导致活产几率降低(OR,0.80;95%CI[0.78, 0.83];P<.001)。在完成的新鲜移植中,非适应证ICSI与IVF的临床妊娠率和活产率相当。在多变量模型中,有PGT和无PGT的冻融周期中的非适应证ICSI与IVF的活产率和临床妊娠率相当。
与IVF相比,新鲜周期中非适应证ICSI与囊胚可利用性降低相关,导致活产率降低。完成移植的结局在临床上相当。